Amgen cuts price of cholesterol drug Repatha by 60 percent

By Deena Beasley (Reuters) - Amgen Inc , looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the U.S.

Reuters October 25, 2018 03:05:05 IST
Amgen cuts price of cholesterol drug Repatha by 60 percent

Amgen cuts price of cholesterol drug Repatha by 60 percent

By Deena Beasley

(Reuters) - Amgen Inc , looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the U.S. biotechnology company said on Wednesday.

Repatha and rival drug Praluent from partners Regeneron Pharmaceuticals Inc and Sanofi SA were launched in 2015 at list prices of more than $14,000 a year.

Sales of both - members of a class known as PCSK9 inhibitors that dramatically lower bad LDL cholesterol - have been constrained by onerous roadblocks to patient access by insurers looking to limit spending on the expensive drugs.

Amgen's move "is clearly focussed on helping patients afford the medicine at the pharmacy counter," said Murdo Gordon, the company's head of commercial operations.

He said the drug, which has been shown to reduce the risk of heart attacks in high-risk patients, needs to be affordable to patients on Medicare, the federal government's health plan for seniors.

Amgen and other drugmakers have assistance programs to cover co-pays and deductibles for patients covered by commercial insurance, but are barred by law from paying those costs for people on government-funded health plans.

The new $5,850 price is in line with the current net price Amgen gets after discounts and rebates to pharmacy benefit managers (PBMs) and health insurers, said Amgen spokeswoman Kristen Davis.

In May, Regeneron and Sanofi agreed with pharmacy benefit manager Express Scripts Holding Co to lower Praluent's price to between $4,500 and $8,000 in exchange for easier access for patients covered by the PBM's largest plan.

Express Scripts still lists Regeneron's drug as the preferred PCSK9 option under that plan, but said on Wednesday it may "re-evaluate based on Amgen’s update."

“Amgen is taking an important step forward to help payers be better positioned to provide breakthrough medicines and help people achieve better outcomes,” Express Scripts' Chief Medical Officer Steve Miller said in a statement.

Amgen estimates that 75 percent of Repatha prescriptions for Medicare patients are not filled due to high out-of-pocket costs.

Gordon said Amgen expects that with the new lower list price for Repatha, Medicare Part D plans will list the drug with a fixed co-pay, rather than require patients to cover a percentage of the drug's price as most now do.

He said nearly half of the 3.4 million Americans estimated to be eligible for treatment with Repatha are on Medicare. Currently, the drug is being used by around 50,000 patients worldwide, Amgen said.

"In the long term it is our hope that we can address more patient needs, leading ultimately to higher revenue," Gordon said.

Despite initial forecasts for multibillion-dollar sales, worldwide sales of Repatha totalled just $271 million in the first half of 2018. Sales of Praluent were $134 million in the same period.

Amgen said the new list price will take affect immediately for most Repatha sales, and said the drug sold under the original list price will be phased out by the end of 2020 in order to limit any disruption to existing contracts.

The company said it has been offering healthcare payers significant rebates this year in exchange for improved patient access to Repatha.

Gordon said Amgen may continue to offer rebates to some PBMs and insurers. "If plans are interested in moving to affordable, fixed co-pay tiers, we are not going to be slow to respond to them," he said.

(Reporting By Deena Beasley; Editing by Bill Berkrot)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Government aid, stock gains push U.S. wealth to pre-pandemic levels, Fed says
Business

Government aid, stock gains push U.S. wealth to pre-pandemic levels, Fed says

By Howard Schneider WASHINGTON (Reuters) - A rebounding stock market and massive federal aid payments pushed the net worth of U.S. households back to pre-coronavirus levels in the second quarter, the Federal Reserve reported on Monday, with savings accounts and equity portfolios both rising sharply despite the pandemic

Traders shun risky assets as new lockdowns loom
Business

Traders shun risky assets as new lockdowns loom

By Rodrigo Campos NEW YORK (Reuters) - Stocks across the world hit their lowest in seven weeks and other risk assets sold off on Monday on concerns over renewed lockdown measures in Europe and Britain, as well as the United States' inability to agree on fiscal stimulus that would support millions of unemployed. Oil prices fell nearly 5%, the dollar rallied and an index of emerging market currencies fell by the most in six months. The MSCI world equity index , which tracks shares in 49 countries, touched its lowest since Aug.

Traders shun risky assets as new lockdowns loom; stocks, oil tumble
Business

Traders shun risky assets as new lockdowns loom; stocks, oil tumble

By Rodrigo Campos NEW YORK (Reuters) - Stocks across the world hit their lowest in seven weeks and other risk assets also sold off on Monday on concerns over renewed lockdown measures in Europe and Britain, as well as the United States' inability to agree on fiscal stimulus that would support millions of unemployed. Oil prices fell more than 3%, the dollar rose against a basket of peers and an index of emerging market currencies fell by the most in six months. The MSCI world equity index , which tracks shares in 49 countries, ended at its lowest since Aug